JCR Pharmaceuticals
4552.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥40.3bn | ¥33.1bn | ¥42.9bn | ¥34.3bn | ¥51.1bn | ¥30.1bn |
| Operating income | ¥368m | −¥6.5bnr | ¥7.5bn | ¥5.1bn | ¥20.1bn | ¥8.6bn |
| Ordinary income | ¥745m | −¥7.1bnr | ¥8.0bn | ¥5.3bn | ¥20.4bn | ¥8.6bn |
| Total assets | ¥107.8bn | ¥103.8bnr | ¥102.1bn | ¥94.6bn | ¥97.0bn | ¥73.7bn |
| Net assets / equity | ¥45.6bn | ¥46.6bnr | ¥56.1bn | ¥52.0bn | ¥50.9bn | ¥38.5bn |
| EPS (basic) | ¥15.74 | ¥-35.91r | ¥51 | ¥29.67 | ¥116.77 | ¥57.33 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 17
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | AnnualAmended | 205 figures · EDINET |
| 2025-04-01 → 2026-03-31 | Annual | 205 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-yearAmended | 68 figures · EDINET |
| 2024-04-01 → 2025-03-31 | AnnualAmended | 205 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 68 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 205 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 69 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 207 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 48 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 207 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 72 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 46 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 207 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 48 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 72 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 46 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 207 figures · EDINET |
21 more reports are still being processed.